

PHARMACEUTICAL 2023



VACCINEX INC. Rank 427 of 446







PHARMACEUTICAL 2023



VACCINEX INC. Rank 427 of 446

The relative strengths and weaknesses of VACCINEX INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of VACCINEX INC. compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 30% points. The greatest weakness of VACCINEX INC. is the variable Assets, Current, reducing the Economic Capital Ratio by 342% points.

The company's Economic Capital Ratio, given in the ranking table, is -386%, being 430% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	7,478
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	2,537
Liabilities, Non-Current	247
Other Assets	310
Other Compr. Net Income	-19,815
Other Expenses	2.0
Other Liabilities	0
Other Net Income	93
Other Revenues	275
Property and Equipment	189
Research and Development	13,979
Selling, General and Administrative Expense	6,202

Output Variable	Value in 1000 USD
Assets	7,977
Liabilities	2,784
Expenses	20,183
Revenues	275
Stockholders Equity	5,193
Net Income	-19,815
Comprehensive Net Income	-29,722
Economic Capital Ratio	-386%

